Cytotoxic Activity of BornUSU I towards T47D Breast Cancer Cells

Nadiya Anandita Nasution; Urip Harahap; Ginda Haro; Hari Purnomo; Denny Satria

doi:10.3889/oamjms.2019.511

Authors

Nadiya Anandita Nasution Department of Pharmacology, Faculty of Pharmacy, University of Sumatera Utara, Medan, Indonesia
Urip Harahap Department of Pharmacology, Faculty of Pharmacy, University of Sumatera Utara, Medan, Indonesia
Ginda Haro Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Sumatera Utara, Medan, Indonesia
Hari Purnomo Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia
Denny Satria Department of Biology, Faculty of Pharmacy, University of Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2019.511

Keywords:

Cytotoxicity, BornUSU I, T47D cells, Breast cancer

Abstract

AIM: The aim of this study was to determine cytotoxic activity of BornUSU I or Boronhafagama I (1,5-bis(4-hydroxyphenyl)-3-oxa-1,5-diaza-2,4-diboropentane-2,4-diol) as a boron derivate compounds which are boron neutron captured theraphy (BNCT) candidates.

METHODS: The T47D cells were treated by BornUSU I, and Tamoxifen as a positive control. The in vitro study was using MTT method with the incubation period for 24h and 48h. All data were determined using viability of cells equation for showing each IC₅₀value.

RESULTS: The IC₅₀ value of BornUSU I and Tamoxifen were 72.61 Â± 0.82 ÂµM and 10.62 Â± 0.06 ÂµM for 24 h incubation period, and for the 48 h incubation period were 44.63 Â± 0.23 ÂµM and 7.79 Â± 0.05 ÂµM. The 48 h incubation period results showed the lowest IC₅₀value.

CONCLUSION: The results reveal that BornUSU I provide effective as anticancer, especially for breast cancer treatment.